Prescribing Unlicensed and Off-Label medicines in the UK

Written by: Prof Sam Shah

Reviewed by a Medico-Legal Expert

Last Reviewed: 
September 2026

Prescribing Unlicensed and Off-Label medicines in the UK

Written by: Prof Sam Shah

Reviewed by a Medico-Legal Expert

Last Reviewed: 
September 2026

A practical guide for clinicians: Prescribing Unlicensed and Off-Label medicines in the UK

As healthcare professionals operating within the UK’s regulatory landscape, we often encounter scenarios demanding the prescription of medicines beyond their licensed indications or formulations. 

Whether it’s an innovative off-label use in paediatrics or a rare condition requiring an unlicensed preparation, understanding the boundaries, responsibilities, and best practices in this area is critical to safeguarding patients and maintaining professional accountability.

The distinction matters: Unlicensed vs. Off-Label

These terms often cause confusion, but they are distinct:

Unlicensed medicines lack a UK marketing authorisation (also called a “product licence”). They include imports, compounded medicines, or “specials” produced specifically for individual patients where no licensed product is available. They might be medicines imported temporarily or bespoke preparations not licensed by the Medicines and Healthcare products Regulatory Agency (MHRA).

Off-label medicines, instead, are licensed medicines when they are used outside their licensed uses, this includes different doses, routes, indications, age groups, or patient populations. For example, prescribing a drug in a pediatric dose when the licence only covers adults.

Both practices are accepted within UK law, but each comes with specific responsibilities. The key is understanding the legal framework and the ethical obligations to patients.

Legal and regulatory framework: Who can prescribe?

In the UK, prescribing authority is assigned based on professional roles, competence, and regulatory standards.

 

Medical Prescribers (Doctors and Dentists)

Doctors and dentists share equivalent prescribing rights as medical prescribers. Both can prescribe licensed, off-label, and unlicensed medicines without formal scope restrictions, provided they prescribe within the limits of their individual clinical skills, training, and experience, and hold appropriate indemnity cover. This means they must be confident and competent in the use of the medicine for the specific indication and patient.

Their professional accountability is paramount: they bear full responsibility for ensuring patient safety and justifying prescribing decisions. This includes adhering to evidence-based practice, obtaining informed patient consent, and thorough documentation.

 

Non-Medical Independent Prescribers (Nurse independent prescribers, Pharmacists independent prescribers)

Nurse Independent Prescribers are authorised to prescribe licensed medicines off-label and unlicensed medicines, provided they have the appropriate qualifications, clinical competence, and follow regulatory frameworks and organisational governance.

Pharmacist Independent Prescribers, similarly to nurse prescribers, can prescribe licensed medicines off-label and unlicensed medicines within their scope of practice, following professional and legal requirements.

 

Supplementary Prescribers (can include nurses, pharmacists, midwives, allied health professionals)

Supplementary prescribers can prescribe under a Clinical Management Plan (CMP). Their prescribing typically includes licensed medicines, and may include unlicensed or off-label use subject to local policies and the CMP’s terms.

 

Optometrist Independent Prescribers

Optometrist prescribers can prescribe licensed medicines off-label but are not permitted to prescribe unlicensed medicines under current regulations.

Prescribing responsibilities: The ethical and practical framework

Across all prescribers, there are shared responsibilities:

  • Confirm that prescribing an unlicensed or off-label medicine is clinically justified and in the patient’s best interest
  • Clearly inform the patient or their carers about the unlicensed or off-label status, associated risks, and alternatives
  • Obtain informed consent and document this discussion
  • Record the rationale for the choice and any monitoring arrangements in the patient’s medical notes
  • Monitor for effectiveness and adverse effects, reporting to pharmacovigilance systems as appropriate.

 

Prescribing outside the licensed indications extends the scope of clinical innovation but should never compromise patient safety. The key principles include:

  • Patient-Centered Decision-Making: Always ensure the patient (or their guardians) understand the unlicensed or off-label nature of the medication scheme. Honest discussions about the potential benefits, risks, and any uncertainties foster trust and shared decision-making.
  • Evidence and Justification: Rely on high-quality evidence, guidelines, or expert consensus to support your decision. When evidence is limited, clearly acknowledge this and document your rationale.
  • Record Keeping : Accurate, clear, and comprehensive documentation is non-negotiable. Record the indication, reasons for deviation from licensing, discussions with the patient, and the monitoring plan.
  • Monitoring and Follow-up: Plan for close monitoring of efficacy and adverse effects, especially for unlicensed products where safety data may be less complete.
  • Reporting: Report adverse events via the Yellow Card Scheme or other pharmacovigilance systems to help build a better understanding of the safety profile of these medicines.

Practical Challenges 

While prescribing unlicensed and off-label medicines is often necessary, it does come with complications:

  • Supply issues: Unlicensed medicines may be hard to source or expensive.
  • Liability concerns: Prescribers are responsible for their decisions; legal protection depends on proper justification and documentation.
  • Patient acceptance: Patients may have concerns about unlicensed or off-label use; transparent communication is essential.

 

To minimise these risks, remember to engage with your pharmacy colleagues early, seek specialist advice when in doubt, and always check organisational policies.

Resources and Further Reading

  • Medicines and Healthcare products Regulatory Agency (MHRA): Offers guidance on unlicensed and off-label use.
  • NHS and professional bodies: Provide position statements and guidelines on best practices.
  • Greenanna et al., 2017, Unlicensed and Off-Label Uses of Medicines: Definitions, Regulatory Framework, and Practice Considerations (PubMed).

Final thoughts: Safety first, safety always

Prescription practices involving unlicensed and off-label medicines are inevitable in many clinical scenarios, and when done responsibly, they can be lifesaving. As clinicians, your primary obligation remains to do no harm, to respect patient autonomy, and to practice within your competence and the law.

Treat every prescription with care, with integrity, transparency, and use meticulous attention to detail. When in doubt, consult colleagues, seek specialist advice, and lean on available guidelines.

Maintaining high standards isn’t just about compliance, it’s about safeguarding the very essence of patient-centered care, with safety and professionalism guiding every decision.

Not a Member Yet? Get Protected Today!

If you’re not yet covered or are unsure about the level of protection you have, consider joining our medical defence membership that offers expert advice and support in medico-legal matters. Good Samaritan cover is just one of the many benefits of having robust medical defence protection.

For more information, or to get immediate access to expert advice, contact us today at:

0300 30 32 442
[email protected]